雄激素剥夺疗法/雄激素受体信号抑制剂治疗前列腺癌:病理生理学和对心血管疾病影响的综述
Richard Orji, Alicia Morgans1, Eiman Jahangir2
1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Southern medical journal
|May 3, 2024
概括
前列腺癌的雄激素剥夺疗法可能会由于抑制或药物导致心血管问题. 对接受这种治疗的患者来说,定期进行心脏查至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 雄激素剥夺疗法 (ADT) 是晚期前列腺癌的主要治疗方法.
- ADT会诱导阴性腺,并涉及可能产生副作用的药物.
- 心血管并发症是与ADT相关的一大问题.
研究的目的:
- 审查与ADT和雄激素受体信号抑制剂 (ARSI) 相关的心血管并发症.
- 突出ADT/ARSI与特定心血管事件之间的关联.
- 强调在接受ADT的前列腺癌患者心血管监测的重要性.
主要方法:
- 系统的文献审查.
- 对ADT,ARSI和心血管结果的研究进行了批判性分析.
- 综合有关心血管风险的证据.
主要成果:
- ADT和ARSI与延长的QT间隔,心房动和心力衰竭有关.
- 增加动脉样硬化,冠心病,静脉血栓栓塞和外周动脉封闭性疾病的风险.
- 对心血管的不良影响源于诱导性阴性恋和治疗药物.
结论:
- 在前列腺癌患者中,ADT和ARSI显著增加心血管风险.
- 在ADT期间,主动的心血管查和管理是必不可少的.
- 需要进一步的研究来减轻这些心血管风险.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
159
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
159
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
799
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
799
Antihypertensive Drugs: Angiotensin II Receptor Blockers
716
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
Antihypertensive Drugs: Direct Renin Inhibitors
606
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
606
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169


